Skip to content
The Uromigos cover art

All episodes

The Uromigos, 501 episodes. Page 2 of 6.

#
Title
101

Episode 444: ESMO 2025 Preview - Prostate and Renal Cancer

102

Episode 443: ESMO 2025 Bladder Cancer Preview

103

Episode 441: The History of IO in Urothelial Cancer - Part 2

104

Episode 440: The History of IO in Urothelial Cancer - Part 1

105

Episode 439: Transcriptome Expression and Treatment Sensitivity in Prostate Cancer

106

Episode 438: The History of Testis Cancer Treatment

107

Episode 437: Uromigos Japan - バルバーサ (Erdafitinib)を実臨床でどう使うか!

108

Episode 436: The History of IO in RCC - Part 2

109

Episode 435: The History of IO in RCC - Part 1

110

Episode 434: IMPACT series - A Walk Through the History of VEGF TKI Development in RCC

111

Episode 433: Uromigos Japan - 改訂版ASCO mCRPCガイドライン

112

Episode 432: ASCO 2025 Rapid Oral Session RCC/Bladder Recap

113

Episode 431: IMPACT series - Axel Bex on Impactful RCC Clinical Trials

114

Episode 430: Structured Exercise Improves DFS/OS after Adjuvant Therapy in Colorectal Cancer - Does This Apply to GU Cancers?

115

Episode 429: ASCO2025レポート

116

Episode 428: ASCO 2025 Recap

117

Episode 427: Emerging Data in Non-muscle Invasive Bladder Cancer (NMIBC)

118

Episode 426 - ASCO 2025: AMPLITUDE Phase 3 of PARPi in mHSPC

119

Episode 425: ASCO 2025 - AI-enabled selection of patients for benefit of ADT + ARPI

120

Episode 424: ASCO 2025 - Emergency podcast on the prostate rapid oral session

121

Episode 423: ASCO 2025 - Casdatifan plus Cabo in refractory RCC

122

Episode 422: ACSO 2025 - ctDNA data from NIAGARA

123

Episode 421: ASCO 2025 - Maintenance Avelumab +/- SG in Advanced Bladder Cancer

124

Episode 420: ASCO 2025 - CheckMate 901: Ipi/Nivo vs chemo for Cis-ineligible metastatic urothelial cancer

125

Episode 419: ASCO 2025 - Correlate data from the IMmotion 010 RCC adjuvant study

126

Episode 418: ASCO 2025 - Biomarkers in RCC

127

Episode 417: ASCO25 GUの注目演題について3人でDiscussion!!

128

Episode 416: ASCO 2025 Preview

129

Episode 415: Uromigos Score 前立腺がん編

130

Episode 414: Uromigos score en cáncer de próstata metastasico - más allá de las guías clínicas

131

Episode 413: The Uromigos Score for Advanced Prostate Cancer

132

Episode 410: AUA 2025 - BOND-003 Cohort C: Cretostimogene in BCG-Unresponsive NMIBC

133

Episode 412: AUA 2025 - TAR-200 Monotherapy in BCG-Unresponsive NMUIBC from SunRISe-1

134

Episode 411: Live from EIKCS in Amsterdam - RCC Highlights

135

Episode 409: AUA 2025 - CREST - BCG +/- Sasanlimab in high-risk NMIBC

136

Episode 408: Uromigos Japan - European Delphi Study of mRCCについてdiscussion

137

Episode 407: Drug Development in China: Part 2 of 2

138

Episode 406: Drug Development in China: Part 1 of 2

139

Episode 405: The Good News About Cancer podcast

140

Episode 404: 177 Lu-PSMA Pre-chemotherapy in mCRPC. Final Podcast from the Canary Islands

141

Episode 403: ADCs in Bladder Cancer. Part 2 from the Canary Islands

142

Episode 402: Uromigos en Espanol: Futuro del carcinoma de células renales

143

Episode 401: ADCs in Bladder Cancer. Part 1 from the Canary Islands

144

Episode 400: The Uromigos Score for Urothelial Cancer

145

Episode 399: A PD1/VEGF Bispecific in Lung Cancer - Lessons for GU Cancers?

146

Episode 398: Reflections on the Felix Feng Symposium at ASCO GU

147

Episode 397: APCCC Diagnostics Conference recap

148

Episode 396: Uromigos Japan - 激論 @JSMO25

149

Episode 395: Uromigos Japan: ASCO GU 2025のレビュー

150

Episode 394: APCCC (Advanced Prostate Cancer Consensus Conference) Diagnostics 2025

151

Episode 393: ASCO GU 2025 Review Podcast

152

Episode 392: ASCO GU 2025 - HIF Inhibition with Casdatifan in Refractory RCC

153

Episode 391: ASCO GU 2025 - KIM-1 Data from Checkmate 214

154

Episode 390: ASCO GU 2025 - Pembro-based Doublets in Refractory RCC and COSMIC-313 OS Update

155

Episode 388: ASCO GU 2025 - FGF3 Inhibition with LOXO-435 in Urothelial Cancer

156

Episode 387: ASCO GU 2025 -Neoadjuvant Disitamab Vedotin + Toripalimab in HER2+ MIBC: updated efficacy and safety results

157

Episode 389: ASCO GU 2025 - NIAGARA Pathologic CR Updates and Outcomes

158

Episode 386: ASCO GU 2025 - APRI Meta-analysis

159

Episode 385: ASCO GU 2025 - TALAPRO-2

160

Episode 384: ASCO GU Preview

161

Episode 383: A Neoantigen Vaccine Generates Anti-tumor Immunity in RCC

162

Episode 382: Uromigos Japan - TROPICs-04の考察

163

Episode 381: Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade

164

Episode 380: The Role of SBRT in RCC

165

Episode 379: Uromigos Japan: 2024年のGU Oncologyを振り返る

166

Episode 378: 2025 Preview of Important GU Data

167

Episode 377: Prostate Cancer 2024 Highlights

168

Episode 376: Bladder Cancer 2024 Highlights

169

Episode 375: Renal Cancer 2024 Highlights

170

Episode 374: Mechanisms of HIF Resistance

171

Episode 373: KEYNOTE-564 Asian OSとANNARの解説

172

Episode 372: FDA Accelerated Approval Process

173

Episode 371: TROPICS-04 Results from ESMO Asia

174

Episode 370: Artificial Intelligence in Medical Oncology

175

Episode 369: Paper of the Month with Bishoy Faltas

176

Episode 368: Radiomics in RCC: Live from IKCS

177

Episode 367: Abiraterone vs AR inhibitors (Fanta vs Coke) in Prostate Cancer

178

Episode 366: ARPIs in Prostate Cancer - Are They Different?

179

Episode 365: A Review of the Advanced Prostate Cancer Consensus Conference (APCCC)

180

Episode 364: 腎がんの最新の話題〜IO rechallengeと乳頭型腎がんの治療戦略〜

181

Episode 363: 前立腺がんの最新の話題〜T cell directed therapyとradioligands〜

182

Episode 362: 膀胱がんの最新の話題〜周術期薬物療法とADC〜

183

Episode 361: The Role of Monotherapy AR Inhibition in Prostate Cancer

184

Episode 360: The SUNRISE Program in Bladder Cancer

185

Episode 359: #UromigosLive24 - IO after IO in RCC

186

Episode 358: Noticias del Dia 1 de Uromigos Live 2024 en Nashville

187

Episode 357: #UromigosLive24 - Peri-operative Therapy in Bladder Cancer

188

Episode 356: #UromigosLive24 - Front-line Therapy in Papillary and Non-clear Cell RCC

189

Episode 355: #UromigosLive24 - Radioligands in prostate cancer

190

Episode 354: #UromigosLive24 - T cell directed therapy in prostate cancer

191

Episode 353: #UromigosLive24 ADC session

192

Episode 352: ESMO 2024 - RCC and Bladder review

193

Episode 351: ESMO 2024 review part 1: prostate cancer

194

Episode 350: ESMO 2024 - NIAGARA

195

Episode 349: ESMO 2024 - Uromigos Japan!!

196

Episode 348: ESMO 2024 - UpFrontPSMA

197

Episode 347: ESMO 2024 - DV + Pembro in Urothelial Cancer

198

Episode 346: ESMO 2024 - PEACE-3: Enza/Radium-223 vs Enza in mCRPC

199

Episode 345: ESMO 2024 - SUNNIFORECAST: Ipi/Nivo vs SOC in Non-clear Cell RCC

200

Episode 344: ESMO 2024 - NKT2152, a HIF inhibitor in RCC